EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH

View source ↗

Summary

EMA authorises Vabysmo (faricimab) for wet macular degeneration, macular edema, and diabetes-related eye complications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Complications
• Macular Edema
• Wet Macular Degeneration

Drugs mentioned

• VABYSMO (faricimab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications. MAH: Roche Registration GmbH. Decision date: 25/06/2026